The CRISPR Crusade: Intellia's Ambitious Leap into the Heart of AML
The Long Road to Hope: Anavex's Alzheimer's Drug Hits a Regulatory Wall
Monopar's Breakthrough in Wilson Disease: A New Dawn with AstraZeneca's Shadow
Biohaven's Breakthrough Bid: Navigating FDA Flexibility for Spinocerebellar Ataxia's Future